Skip to main content
Top
Published in: Familial Cancer 3/2012

01-09-2012 | Original Article

Causes of death of mutation carriers in Finnish Lynch syndrome families

Authors: Kirsi Pylvänäinen, Tuula Lehtinen, Ilmo Kellokumpu, Heikki Järvinen, Jukka-Pekka Mecklin

Published in: Familial Cancer | Issue 3/2012

Login to get access

Abstract

Lynch syndrome (LS) is an autosomal dominant cancer syndrome including increased life-long risk for colorectal (CRC) and endometrial (EC) cancer, but also for cancers of other types. The risk for CRC is up to 70–80 % and for EC up to 50–60 %. Due to screening and early diagnosing the mortality related to CRC and EC seems to be low. In spite of many studies on surveillance of mutation carriers, there is no comprehensive evaluation on causes of death in LS families. The disease history and cause of death of all the deceased, tested mutation carriers and their mutation negative relatives in the Finnish LS families (N = 179) was examined utilizing hospital records and relevant national registries. Out of 1069 mutation carriers 151 had succumbed; 97 (64 %) from cancer. Out of 1146 mutation-negative family 44 members had died; 11 (25 %) of them from cancer. In 12 (7.7 %) of the deceased mutation carriers no cancer had been diagnosed. The mean age of death from cancer was 63.2 years vs. 68.8 years from non-cancer causes. Only 7.9 % of the patients with CRC had died from CRC and 5 % of those with EC, respectively. 61 % of the cancer deaths were related to extra-colonic, extra-endometrial cancers. The cumulative overall and cancer specific death rates were significantly increased in Mut+ compared to Mut− family members. Even surveillance yields decrease in the life-long risk and mortality of the most common cancers CRC and EC in LS, almost all mutation carriers will contract with cancer, and two thirds of the deceased have died from cancer. This should be taken in account in genetic counseling. Mutation carriers should be encouraged to seek help for abnormal symptoms.
Literature
1.
go back to reference Aaltonen L, Johns L, Järvinen H et al (2007) Explaining the familial colorectal cancer risk associating with mismatch repair (MMR) deficient and MMR-stable tumors. Clin Cancer Res 13:356–361PubMedCrossRef Aaltonen L, Johns L, Järvinen H et al (2007) Explaining the familial colorectal cancer risk associating with mismatch repair (MMR) deficient and MMR-stable tumors. Clin Cancer Res 13:356–361PubMedCrossRef
2.
go back to reference Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef
3.
go back to reference Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421PubMed Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421PubMed
4.
go back to reference Mecklin J-P, Aarnio M, Läärä E et al (2007) Development of colorectal tumors in colonoscopic surveillance in Lynch Syndrome. Gastroenterology 133:1093–1098PubMedCrossRef Mecklin J-P, Aarnio M, Läärä E et al (2007) Development of colorectal tumors in colonoscopic surveillance in Lynch Syndrome. Gastroenterology 133:1093–1098PubMedCrossRef
5.
go back to reference Järvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411PubMedCrossRef Järvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411PubMedCrossRef
6.
go back to reference Vasen HFA, Abrdirahman M, Brohet R et al (2010) One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300–2306PubMedCrossRef Vasen HFA, Abrdirahman M, Brohet R et al (2010) One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300–2306PubMedCrossRef
7.
go back to reference Watson P, Vasen HFH, Mecklin J-P et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444–449PubMedCrossRef Watson P, Vasen HFH, Mecklin J-P et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444–449PubMedCrossRef
8.
go back to reference Vasen HF, Wignen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRef Vasen HF, Wignen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRef
9.
go back to reference Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797PubMedCrossRef Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797PubMedCrossRef
10.
go back to reference Järvinen HJ et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef Järvinen HJ et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef
11.
go back to reference Mecklin JP, Järvinen HJ, Peltokallio P (1986) Identification of cancer family syndrome. Gastroenterology 90:1099PubMed Mecklin JP, Järvinen HJ, Peltokallio P (1986) Identification of cancer family syndrome. Gastroenterology 90:1099PubMed
12.
go back to reference Pylvänäinen K, Kairaluoma M, Mecklin J-P (2006) Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer 5:173–178CrossRef Pylvänäinen K, Kairaluoma M, Mecklin J-P (2006) Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer 5:173–178CrossRef
13.
go back to reference Parry S, Aung KW, Parry B et al (2011) Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60:950–957PubMedCrossRef Parry S, Aung KW, Parry B et al (2011) Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60:950–957PubMedCrossRef
14.
go back to reference Nieminen T, Gylling A, Abdel-Rahman WM et al (2009) Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 15:5722–5783CrossRef Nieminen T, Gylling A, Abdel-Rahman WM et al (2009) Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 15:5722–5783CrossRef
15.
go back to reference Burn J, Gerdes A-M, Macrae F et al (2011) Long-term effect of aspiring on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087PubMedCrossRef Burn J, Gerdes A-M, Macrae F et al (2011) Long-term effect of aspiring on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087PubMedCrossRef
16.
go back to reference Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kääriäinen H (2001) Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 93:608–611PubMedCrossRef Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kääriäinen H (2001) Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 93:608–611PubMedCrossRef
Metadata
Title
Causes of death of mutation carriers in Finnish Lynch syndrome families
Authors
Kirsi Pylvänäinen
Tuula Lehtinen
Ilmo Kellokumpu
Heikki Järvinen
Jukka-Pekka Mecklin
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2012
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9537-3

Other articles of this Issue 3/2012

Familial Cancer 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine